James J. Burns & Company LLC Acquires 11,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

James J. Burns & Company LLC increased its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) by 11.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 111,111 shares of the company’s stock after purchasing an additional 11,000 shares during the period. James J. Burns & Company LLC’s holdings in Wave Life Sciences were worth $1,374,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Wave Life Sciences by 23.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after buying an additional 856 shares during the period. KBC Group NV bought a new stake in Wave Life Sciences during the 4th quarter valued at approximately $67,000. Point72 DIFC Ltd purchased a new position in shares of Wave Life Sciences during the 3rd quarter worth approximately $98,000. Orion Portfolio Solutions LLC bought a new position in shares of Wave Life Sciences in the 3rd quarter worth approximately $123,000. Finally, XTX Topco Ltd purchased a new stake in Wave Life Sciences in the third quarter worth $126,000. Institutional investors own 89.73% of the company’s stock.

Analyst Ratings Changes

WVE has been the topic of a number of recent research reports. Raymond James raised shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $13.00 to $22.00 in a research report on Wednesday, October 16th. JPMorgan Chase & Co. lifted their target price on shares of Wave Life Sciences from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, October 17th. Truist Financial upped their price target on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. StockNews.com cut Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, November 13th. Finally, Leerink Partners increased their target price on Wave Life Sciences from $20.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.22.

Wave Life Sciences Stock Up 2.5 %

NASDAQ WVE opened at $11.86 on Tuesday. The company has a 50-day moving average price of $13.11 and a 200-day moving average price of $10.42. Wave Life Sciences Ltd. has a 52 week low of $3.50 and a 52 week high of $16.74.

Insider Activity at Wave Life Sciences

In related news, CEO Paul Bolno sold 51,234 shares of Wave Life Sciences stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $14.32, for a total value of $733,670.88. Following the completion of the transaction, the chief executive officer now owns 217,351 shares in the company, valued at approximately $3,112,466.32. This trade represents a 19.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Chris Francis sold 36,000 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $576,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 137,234 shares of company stock valued at $2,059,671. 29.10% of the stock is owned by company insiders.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.